Business
MDxHealth Announces Launch of Offering of ADSs in the United States
NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 1, 2023, 4PM ET/ 22:00 CET MDxHealth Announces Launch of Offering of ADSs in the United States
About this update from Mdxhealth Sa
[{"type":"text","content":"NEWS RELEASE – REGULATED INFORMATIONINSIDE INFORMATIONFEBRUARY 1, 2023, 4PM ET/ 22:00 CET MDxHealth Announces Launch of Offering of ADSs in the United States IRVINE, CA, and HERSTAL, BELGIUM –February 1, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, announced the launch of a proposed offering of $40,000,000 of American Depositary Shares (\"ADSs\") (each representing 10 ordinary shares of the Company without nominal value) in a registered public offering (the “Offering”). The Company also expects to grant the underwriters a 30-day option to purchase up to 15% of the ADSs being offered. Cowen and Company, LLC and William Blair & Company, L.L.C. are acting as joint book-running managers, BTIG, LLC is acting as a lead manager, and KBC Securities USA LLC is acting as a co-manager for the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering, including the price per ADS and number of ADSs sold in the Offering. The ADSs described above are being offered by mdxhealth pursuant to a registration statement previously filed with and subsequently declared effective by the Securities and Exchange Commission (“SEC”). A preliminary prospectus supplement relating to the Offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov. This press release does not constitute an offer to sell or a solicitation of an offer to buy securities of the Company nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities, if at all, will be made in accordance with the registration requirements of the United States Securities Act of 1933 and the European Prospectus Regulation (Regulation (EU) 2017/1129), as relevant. Copies of the preliminary prospectus supplement, and accompanying base prospectus relating to this offering, may be obtained from Cowen and Company, LLC, 599 Lexington Avenue, New...